Related Experiment Video
Updated: Jun 6, 2026
05:10
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
Published on: October 3, 2010
Childhood medulloblastoma
Maura Massimino1, Felice Giangaspero, Maria Luisa Garrè
1Fondazione IRCCS "Istituto Nazionale dei Tumori", Milan, Italy. START@istitutotumori.mi.it
Critical Reviews in Oncology/Hematology
|December 7, 2010
Summary
Medulloblastoma, a common childhood brain tumor, shows improved survival rates. Ongoing trials aim to identify molecular markers for better risk stratification and treatment outcomes in pediatric patients.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Cancer Genomics
Background:
- Medulloblastoma and primitive neuroectodermal tumors (PNET) represent 16-25% of pediatric central nervous system tumors.
- Etiology remains largely unknown, with a higher incidence in males and children versus adults.
- Significant survival improvements observed for children diagnosed between 2000-2002 compared to 1995-1999, with a 30% reduction in mortality risk.
Purpose of the Study:
- To identify molecular and biological markers for improved outcome prediction in medulloblastoma.
- To incorporate these markers for front-line stratification of newly defined risk subgroups.
- To enhance risk-stratified treatment schemes for pediatric medulloblastoma patients.
Main Methods:
- Analysis of patient data stratified by age, extent of residual disease, and tumor dissemination.
- Review of risk-stratified schemes used in North American trials.
- Focus on defining molecular and biological markers for prognostic value.
Main Results:
- Patients are stratified into average-risk (60-70% of those >3 years) and high-risk groups.
- High-risk criteria include disseminated disease or >1.5 cm² of post-operative residual disease.
- Survival rates have significantly improved in recent diagnostic cohorts.
Conclusions:
- Current clinical trials focus on refining risk stratification through molecular markers.
- Improved outcome prediction will lead to more personalized treatment strategies.
- Advancements in pediatric medulloblastoma treatment are evident through improved survival statistics.
Related Concept Videos
01:20The Retinoblastoma Gene
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:20The Retinoblastoma Gene
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...